Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Current Assets (2016 - 2025)

Historic Current Assets for Anaptysbio (ANAB) over the last 11 years, with Q3 2025 value amounting to $330.6 million.

  • Anaptysbio's Current Assets fell 2630.62% to $330.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.6 million, marking a year-over-year decrease of 2630.62%. This contributed to the annual value of $431.9 million for FY2024, which is 615.51% up from last year.
  • Anaptysbio's Current Assets amounted to $330.6 million in Q3 2025, which was down 2630.62% from $291.9 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Current Assets ranged from a high of $553.9 million in Q4 2021 and a low of $291.9 million during Q2 2025
  • For the 5-year period, Anaptysbio's Current Assets averaged around $416.1 million, with its median value being $428.0 million (2023).
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 3966.98% in 2021, then plummeted by 2630.62% in 2025.
  • Anaptysbio's Current Assets (Quarter) stood at $553.9 million in 2021, then decreased by 19.26% to $447.2 million in 2022, then decreased by 9.03% to $406.8 million in 2023, then increased by 6.16% to $431.9 million in 2024, then fell by 23.44% to $330.6 million in 2025.
  • Its Current Assets stands at $330.6 million for Q3 2025, versus $291.9 million for Q2 2025 and $363.1 million for Q1 2025.